ReviewSystematic reviews2019

The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review.

Miriam Van den Nest et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.